药代动力学
药效学
药理学
医学
临床试验
机制(生物学)
计算生物学
内科学
生物
认识论
哲学
作者
Paul Morgan,Piet H. van der Graaf,John E. Arrowsmith,Douglas E. Feltner,Kira S. Drummond,Craig D. Wegner,Stephen D. A. Street
标识
DOI:10.1016/j.drudis.2011.12.020
摘要
In an effort to uncover systematic learnings that can be applied to improve compound survival, an analysis was performed on data from Phase II decisions for 44 programs at Pfizer. It was found that not only were the majority of failures caused by lack of efficacy but also that, in a large number of cases (43%), it was not possible to conclude whether the mechanism had been tested adequately. A key finding was that an integrated understanding of the fundamental pharmacokinetic/pharmacodynamic principles of exposure at the site of action, target binding and expression of functional pharmacological activity (termed together as the 'three Pillars of survival') all determine the likelihood of candidate survival in Phase II trials and improve the chance of progression to Phase III.
科研通智能强力驱动
Strongly Powered by AbleSci AI